Versant and Lilly Back $100M Gene Therapy Startup
Versant Ventures, Eli Lilly, and a group of additional investors are committing $100 million to launch a new startup aimed at tackling one of gene therapy's most persistent problems, according to STAT News.
The backing matters because gene therapy has delivered dramatic clinical results but remains held back by stubborn technical and commercial obstacles, including how to deliver genetic payloads safely, how to make effects durable, and how to manufacture treatments at scale and reasonable cost. A $100 million round led by a top-tier venture firm and a major pharmaceutical company signals that investors still see large upside in solving these foundational issues rather than chasing individual disease programs.
For operators and investors, the deal is a reminder that capital is flowing toward platform-level fixes in gene therapy, where a breakthrough could unlock many downstream treatments. Eli Lilly's involvement also reflects how large drugmakers are partnering early with startups to secure access to next-generation delivery and durability technology.
Sources